Susquehanna Fundamental Investments’s TG Therapeutics TGTX Stock Holding History

Susquehanna Fundamental Investments’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-8,950	Closed	-$353K	–	996
2025 Q1	$353K	Sell	8,950 -700	-7%	-$23.6K	﹤0.01%	923
2024 Q4	$290K	Buy	+9,650	New	+$277K	﹤0.01%	948
2023 Q4	–	Sell	-198,137	Closed	-$1.66M	–	309
2023 Q3	$1.66M	Sell	198,137 -46,961	-19%	-$655K	0.11%	158
2023 Q2	$6.09M	Hold	245,098	–	–	0.22%	127
2023 Q1	$3.69M	Hold	245,098	–	–	0.09%	265
2022 Q4	$2.9M	Buy	+245,098	New	+$1.78M	0.05%	392

Other funds holding TGTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Susquehanna Fundamental Investments's TGTX Position: Q2 2025 in Review

Susquehanna Fundamental Investments sold out of TG Therapeutics (TGTX) in Q2 2025, closing a stake of 8,950 shares — an estimated $353K sold.

Susquehanna Fundamental Investments first reported a position in TGTX in Q4 2022 and held it in 6 quarters. The position peaked at $6.09M in Q2 2023. 356 funds tracked by Wall St. Rank hold TGTX as of Q2 2025.

Susquehanna Fundamental Investments reported no remaining TG Therapeutics position as of Q2 2025 after selling out during the quarter.
Susquehanna Fundamental Investments sold 8,950 TG Therapeutics shares in Q2 2025, an estimated $353K.
Susquehanna Fundamental Investments first reported a position in TG Therapeutics in Q4 2022 and held it in 6 quarters.
Susquehanna Fundamental Investments's TG Therapeutics position peaked at $6.09M in Q2 2023.
356 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2025.

Based on Susquehanna Fundamental Investments's 13F filing for Q2 2025, filed 14 Aug 2025.